AbstractTo better understand the limits of antigenic reactivity and epitope accessibility of the V3 domain of primary HIV-1 isolates, we evaluated three human anti-V3 monoclonal antibodies (mAbs) and selected guinea pig vaccine sera for neutralization against reference panels of subtype B and C pseudoviruses derived from early stage infections. The mAbs and vaccine sera potently neutralized several prototype viruses, but displayed substantially less neutralization of most reference strains. In the presence of soluble CD4 (sCD4), the breadth of V3-mediated neutralization was increased; up to 80% and 77% of the subtype B and C viruses respectively were sensitive to V3-mediated neutralization. Unlike sCD4, the reaction of CD4-binding site mAbs...
The V3 loop of the HIV-1 envelope (Env) glycoprotein gp120 was identified as the “principal neutrali...
#<p>Neutralization epitope in the Gp120 outer domain before CD4 binding.</p>$<p>Neutralization epito...
AbstractRabbits were immunized with a novel regimen designed to focus the immune response on a singl...
AbstractThe identification of cross-neutralizing antibodies to HIV-1 is important for designing anti...
Summary: Despite recent progress in engineering native trimeric HIV-1 envelope glycoprotein (Env) mi...
AbstractTwo human monoclonal anti-HIV-1 antibodies, 2F5 and 4E10, were utilized to investigate the a...
The V3 loop of the HIV-1 envelope (Env) glycoprotein gp120 was identified as the "principal neutrali...
SummaryThe third variable (V3) loop and the CD4 binding site (CD4bs) of the HIV-1 envelope are frequ...
The early autologous neutralizing antibody response in human immunodeficiency virus type 1 (HIV-1) s...
Abstract Background The CD4-induced (CD4i) epitopes in gp120 includes the co-receptor binding site, ...
The envelope glycoproteins of HIV, gp120 and gp41, contain epitopes recognized by neutralizing antib...
The limited neutralizing activity of V3 antibodies is typically attributed to V3 masking. While rela...
The early autologous neutralizing antibody response in human immunodeficiency virus type 1 (HIV-1) s...
The third variable (V3) loop and the CD4 binding site (CD4bs) of the HIV-1 envelope are frequently t...
AbstractThe HIV-1 gp120 V3 loop is a potent inducer of neutralizing antibodies for T cell line adapt...
The V3 loop of the HIV-1 envelope (Env) glycoprotein gp120 was identified as the “principal neutrali...
#<p>Neutralization epitope in the Gp120 outer domain before CD4 binding.</p>$<p>Neutralization epito...
AbstractRabbits were immunized with a novel regimen designed to focus the immune response on a singl...
AbstractThe identification of cross-neutralizing antibodies to HIV-1 is important for designing anti...
Summary: Despite recent progress in engineering native trimeric HIV-1 envelope glycoprotein (Env) mi...
AbstractTwo human monoclonal anti-HIV-1 antibodies, 2F5 and 4E10, were utilized to investigate the a...
The V3 loop of the HIV-1 envelope (Env) glycoprotein gp120 was identified as the "principal neutrali...
SummaryThe third variable (V3) loop and the CD4 binding site (CD4bs) of the HIV-1 envelope are frequ...
The early autologous neutralizing antibody response in human immunodeficiency virus type 1 (HIV-1) s...
Abstract Background The CD4-induced (CD4i) epitopes in gp120 includes the co-receptor binding site, ...
The envelope glycoproteins of HIV, gp120 and gp41, contain epitopes recognized by neutralizing antib...
The limited neutralizing activity of V3 antibodies is typically attributed to V3 masking. While rela...
The early autologous neutralizing antibody response in human immunodeficiency virus type 1 (HIV-1) s...
The third variable (V3) loop and the CD4 binding site (CD4bs) of the HIV-1 envelope are frequently t...
AbstractThe HIV-1 gp120 V3 loop is a potent inducer of neutralizing antibodies for T cell line adapt...
The V3 loop of the HIV-1 envelope (Env) glycoprotein gp120 was identified as the “principal neutrali...
#<p>Neutralization epitope in the Gp120 outer domain before CD4 binding.</p>$<p>Neutralization epito...
AbstractRabbits were immunized with a novel regimen designed to focus the immune response on a singl...